Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-15T11:53:42.122Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of SSRIs May Impact Bone Density in Adolescent and Young Women With Anorexia Nervosa

Published online by Cambridge University Press:  07 November 2014

Madhusmita Misra ,
Marie Le Clair ,
Nara Mendes ,
Karen K. Miller ,
Elizabeth Lawson ,
Erinne Meenaghan ,
Thomas Weigel ,
Seda Ebrahimi ,
David B. Herzog  and
Anne Klibanski
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: Alterations in serotonin impact bone metabolism in animal models, and selective serotonin reuptake inhibitors (SSRIs) have been associated with increased fracture risk in older adults. SSRIs are commonly used in anorexia nervosa (AN), a condition that predisposes to low bone mineral density (BMD). Our objective was to determine whether SSRI use is associated with low BMD in AN.

Methods: We examined Z-scores for spine, hip, and whole body (WB) BMD, spine bone mineral apparent density, and WB bone mineral content/height (BMC/Ht) in females 12–21 years of age with AN who had never been on SSRIs, had been on SSRIs for <6 months (<6M), or had been on SSRIs for >6 months (>6M).

Results: Subjects on SSRIs for >6M had lower spine, femoral-neck, and WBBMD Z-scores than those on SSRIs for <6M. Hip BMD and WBBMC/Ht Z-scores were lowest in subjects on SSRIs for >6M. Duration of SSRI use, duration since AN diagnosis and duration of amenorrhea inversely predicted BMD, whereas BMI was a positive predictor. In a regression model, duration of SSRI use remained an independent negative predictor of BMD.

Discussion: Duration of SSRI use >6M is associated with low BMD in AN.

Conclusion: It may be necessary to monitor BMD more rigorously when duration of SSRI use exceeds 6M.

Type
Original Research
Information
CNS Spectrums , Volume 15 , Issue 9 , September 2010 , pp. 579 - 586
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Grinspoon, S, Miller, K, Coyle, C, et al. Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea. J Clin Endocrinol Metab. 1999;84(6):2049–2055.Google ScholarPubMed
2.Hay, PJ, Delahunt, JW, Hall, A, Mitchell, AW, Harper, G, Salmond, C. Predictors of osteopenia in premenopausal women with anorexia nervosa. Calcif Tissue Int. 1992;50(6):498–501.CrossRefGoogle ScholarPubMed
3.Lennkh, C, de Zwaan, M, Bailer, U, et al. Osteopenia in anorexia nervosa: specific mechanisms of bone loss. J Psychiatr Res. 1999;33(4):349–356.CrossRefGoogle ScholarPubMed
4.Rigotti, NA, Neer, RM, Skates, SJ, Herzog, DB, Nussbaum, SR. The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA. 1991;265(9):1133–1138.Google ScholarPubMed
5.Misra, M, Aggarwal, A, Miller, KK, et al. Effects of anorexia nervosa on clinical, hematologic, biochemical, and bone density parameters in community-dwelling adolescent girls. Pediatrics. 2004;114(6):1574–1583.CrossRefGoogle ScholarPubMed
6.Misra, M, Klibanski, A. Anorexia nervosa and osteoporosis. Rev Endocr Metab Disord. 2006;7(1–2):91–99.CrossRefGoogle ScholarPubMed
7.Soyka, LA, Grinspoon, S, Levitsky, LL, Herzog, DB, Klibanski, A. The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab. 1999;84(12):4489–4496.Google Scholar
8.Misra, M, McGrane, J, Miller, KK, et al. Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa. Bone. 2009;45(3):493–498.CrossRefGoogle ScholarPubMed
9.Misra, M, Miller, KK, Bjornson, J, et al. Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J Clin Endocrinol Metab. 2003;88(12):5615–5623.CrossRefGoogle ScholarPubMed
10.Lawson, EA, Misra, M, Meenaghan, E, et al. Adrenal glucocorticoid and androgen precursor dissociation in anorexia nervosa. J Clin Endocrinol Metab. 2009;94(4):1367–1371.CrossRefGoogle ScholarPubMed
11.Misra, M, Miller, KK, Almazan, C, et al. Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J Clin Endocrinol Metab. 2004;89(10):4972–4980.CrossRefGoogle ScholarPubMed
12.Misra, M, Miller, KK, Cord, J, et al. Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. J Clin Endocrinol Metab. 2007;92(6):2046–2052.CrossRefGoogle ScholarPubMed
13.Misra, M, Miller, KK, Tsai, P, et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab. 2006;91(3):1027–1033.CrossRefGoogle ScholarPubMed
14.Utz, AL, Lawson, EA, Misra, M, et al. Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. Bone. 2008;43(1):135–139.CrossRefGoogle ScholarPubMed
15.Bachrach, LK, Guido, D, Katzman, D, Litt, IF, Marcus, R. Decreased bone density in adolescent girls with anorexia nervosa. Pediatrics. 1990;86(3):440–447.CrossRefGoogle ScholarPubMed
16.Castro, J, Lazaro, L, Pons, F, Halperin, I, Toro, J. Predictors of bone mineral density reduction in adolescents with anorexia nervosa. J Am Acad Child Adolesc Psychiatry. 2000;39(11):1365–1370.CrossRefGoogle ScholarPubMed
17.Grinspoon, S, Baum, H, Lee, K, Anderson, E, Herzog, D, Klibanski, A. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab. 1996;81(11):3864–3870.Google Scholar
18.Soyka, LA, Misra, M, Frenchman, A, et al. Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab. 2002;87(9):4177–4185.CrossRefGoogle ScholarPubMed
19.Raymond, JR, Mukhin, YV, Gelasco, A, et al. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther. 2001;92(2–3):179–212.CrossRefGoogle ScholarPubMed
20.Baldock, PA, Sainsbury, A, Allison, S, et al. Hypothalamic control of bone formation: distinct actions of leptin and y2 receptor pathways. J Bone Miner Res. 2005;20(10):1851–1857.CrossRefGoogle ScholarPubMed
21.Battaglino, R, Fu, J, Spate, U, et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res. 2004;19(9):1420–1431.CrossRefGoogle ScholarPubMed
22.Bliziotes, MM, Eshleman, AJ, Zhang, XW, Wiren, KM. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone. 2001;29(5):477–486.CrossRefGoogle ScholarPubMed
23.Westbroek, I, van der Plas, A, de Rooij, KE, Klein-Nulend, J, Nijweide, PJ. Expression of serotonin receptors in bone. J Biol Chem. 2001;276(31):28961–28968.CrossRefGoogle ScholarPubMed
24.Kroeze, WK, Kristiansen, K, Roth, BL. Molecular biology of serotonin receptors structure and function at the molecular level. Curr Top Med Chem. 2002;2(6):507–528.CrossRefGoogle ScholarPubMed
25.Warden, SJ, Bliziotes, MM, Wiren, KM, Eshleman, AJ, Turner, CH. Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol Cell Endocrinol. 2005;242(1–2):1–9.CrossRefGoogle ScholarPubMed
26.Warden, SJ, Robling, AG, Sanders, MS, Bliziotes, MM, Turner, CH. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology. 2005;146(2):685–693.CrossRefGoogle ScholarPubMed
27.Sibilia, V, Pagani, F, Lattuada, N, Greco, A, Guidobono, F. Linking chronic tryptophan deficiency with impaired bone metabolism and reduced bone accrual in growing rats. J Cell Biochem. 2009;107(5):890–898.CrossRefGoogle ScholarPubMed
28.Eskandari, F, Martinez, PE, Torvik, S, et al. Low bone mass in premenopausal women with depression. Arch Intern Med. 2007;167(21):2329–2336.CrossRefGoogle ScholarPubMed
29.Haney, EM, Chan, BK, Diem, SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007;167(12):1246–1251.CrossRefGoogle ScholarPubMed
30.Richards, JB, Papaioannou, A, Adachi, JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167(2):188–94.CrossRefGoogle ScholarPubMed
31.Williams, LJ, Henry, MJ, Berk, M, et al. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol. 2008;23(2):84–87.CrossRefGoogle ScholarPubMed
32.Diagnostic and Statistical Manual of Mental Disorders. 4th ed Washington, DC: American Psychiatric Association; 1994.Google Scholar
33.Greulich, W PS. Radiographic Atlas of Skeletal Development of the Hand and Wrist. 2nd ed. Stanford, CA: Stanford University Press; 1959.Google Scholar
34.Carter, DR, Bouxsein, ML, Marcus, R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res. 1992;7(2):137–145.CrossRefGoogle ScholarPubMed
35.Kelley T, SB, Binkley, T, et al. Pediatric BMD Reference Database for US White Children. Sorrento, Italy; 2005.Google Scholar
36.Yadav, VK, Ryu, JH, Suda, N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008;135(5):825–837.CrossRefGoogle ScholarPubMed
37.Gustafsson, BI, Westbroek, I, Waarsing, JH, et al. Long-term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats. J Cell Biochem. 2006;97(6):1283–1291.CrossRefGoogle ScholarPubMed
38.Kinjo, M, Setoguchi, S, Schneeweiss, S, Solomon, DH. Bone mineral density in subjects using central nervous system-active medications. Am J Med. 2005;118(12):1414.CrossRefGoogle ScholarPubMed
39.Bolton, JM, Metge, C, Lix, L, Prior, H, Sareen, J, Leslie, WD. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol. 2008;28(4):384–391.CrossRefGoogle ScholarPubMed
40.Vestergaard, P, Rejnmark, L, Mosekilde, L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006;17(6):807–816.CrossRefGoogle ScholarPubMed
41.Ziere, G, Dieleman, JP, van der Cammen, TJ, Hofman, A, Pols, HA, Stricker, BH. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol. 2008;28(4):411–417.CrossRefGoogle ScholarPubMed
42.Lewis, CE, Ewing, SK, Taylor, BC, et al. Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res. 2007;22(2):211–219.CrossRefGoogle ScholarPubMed
43.Spangler, L, Scholes, D, Brunner, RL, et al. Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med. 2008;23(5):567–574.CrossRefGoogle ScholarPubMed